Trimedyne puts cash into laser revascularisation
This article was originally published in Clinica
Executive Summary
Trimedyne has injected $2 million into its wholly-owned subsidiary, Cardiodyne, and assigned the rights to several lasers to develop a transmyocardial laser revascularisation (TMR) system.